This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Elpiscience filing for a Hong Kong IPO after US$250M in financing, Zhejiang Medicine planning an HKEX spin-off for ADC subsidiary Novocodex, Baoji Pharmaceuticals securing HKEX approval with a valuation over RMB 4.87 billion, and Phrontline Biopharma completing US$60M Pre-A+ financing for its ADC pipeline. Clinical breakthroughs feature Pfizer’s marstacimab as China’s first TFPI antibody for haemophilia, Biokin filing China’s first EGFR/HER3 bispecific ADC NDA, Novartis gaining NMPA approval for remibrutinib in urticaria, Innovent’s PECONDLE® approved as China’s first IL-23p19 antibody for psoriasis, BeOne’s sonrotoclax receiving FDA priority review for lymphoma, and IASO Bio’s Fucaso approved as China’s first CAR-T therapy in Hong Kong.
